Hostname: page-component-78c5997874-g7gxr Total loading time: 0 Render date: 2024-11-10T06:36:50.266Z Has data issue: false hasContentIssue false

PP013 Pain Management And Substance Abuse In Sickle Cell Disease Patients

Published online by Cambridge University Press:  12 January 2018

Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
INTRODUCTION:

Drug abuse is a social and public health problem because of its negative consequences of emotional and physical development in individuals. There are few studies evaluating substance abuse by individuals with sickle cell disease (SCD). These patients have severe and recurrent pain crises (1), frequently needing opioids to control it (2). The compromised quality of life can predispose this population to the occurrence of non-psychotic disorders such as depression, making them vulnerable to substance abuse (3).

METHODS:

We evaluated the consumption of alcohol and drugs in a cohort followed at the Sickle Cell Disease Reference Center (CRAF), at Hospital de Clínicas de Porto Alegre, estimating the percentage of patients in treatment of SCD who abuse alcohol and drugs, mainly opioids. A cross-sectional study was of a convenience sample of 139 patients with SCD treated at CRAF. The pattern of substance use was evaluated using the Brazilian version of Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). The exposure to opioids was measured by their use and prescription in the 24 months before the interview. The Self-Reporting Questionnaire (SRQ-20) was used to estimate the occurrence of non-psychotic disorders in this population. Descriptive analyses were performed using absolute and relative frequencies. The association between the variables was verified using the chi-square test or Fisher's exact test.

RESULTS:

The prevalence of abusive use was 1.5 percent for alcohol and 3.0 percent for tobacco, with no abusive use of any other substance including opioids was identified. Of note was the pattern for substance use that was not influenced by exposure to substances or the presence of non-psychotic disorders.

CONCLUSIONS:

Our data shows that use of opioid analgesics for the management of SCD painful crises is safe and does not induce substance abuse. Regular follow-up of these patients is recommended. The results of this study might be useful in other countries.

Type
Poster Presentations
Copyright
Copyright © Cambridge University Press 2018 

References

REFERENCES:

1. Platt, OS, Thorington, BD, Brambilla, DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med. 1991;325 (1):11–6. PubMed PMID: 1710777. Epub 1991/07/04. eng.CrossRefGoogle ScholarPubMed
2. Smith, WR, Dahman, BA, Levenson, JL, et al. Daily home opioid use in adults with sickle cell disease: The PiSCES project. J Opioid Manag. 2015;11 (3):243–53.CrossRefGoogle ScholarPubMed
3. Marlowe, KF, Chicella, MF. Treatment of sickle cell pain. Pharmacotherapy. 2002;22 (4):484–91.Google Scholar